Predictive Value of Having Positive Family History of Cardiovascular Disorders, Diabetes Mellitus, Dyslipidemia, and Hypertension in Non-Alcoholic Fatty Liver Disease Patients
In the present study, we examined the relationship between family history of cardiovascular diseases (CVD), dyslipidemia, hypertension, and diabetes with laboratorial abnormalities and syndromes in Iranian patients with non-alcoholic fatty liver disease (NAFLD). A total of 332 NAFLD patients from our outpatient clinic were consecutively entered into analysis. Exclusion criteria were having diabetes mellitus and fasting blood glucose over 126, active hepatitis B virus infection, having HCV positive serology, and to be under corticosteroid therapy. Family history of CVD, diabetes, dyslipidemia, and hypertension were taken from patients and related to the study variables. Family history of cardiovascular diseases (CVD) was associated with low HDL levels (P=0.05). Patients with positive family history of diabetes mellitus were significantly more likely to have AST/ALT levels proportion of higher than one (P=0.044). Family history of dyslipidemia was a predictor for hypertriglyceridemia (P=0.02), higher prothrombin time levels (P=0.013), lower albumin (P=0.024) and T4 (P=0.043) levels. Family history of hypertension was associated with dysglycemia/diabetes (P=0.038), high ALT (P=0.008), and low TIBC (P=0.007) and albumin levels (P=0.001). Family history for CVD, diabetes, dyslipidemia, and hypertension were of clinical importance in the Iranian patients with NAFLD. We therefore recommend that physicians should precisely get family history of main disorders in all NAFLD patients; and to pay more attention to those having the mentioned family histories. Further studies with larger patient population and prospective approach are needed for confirming our findings.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl 1):S99-S112.
Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98(5):960-7.
Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. JGastroenterol 2003;38(10):954-61.
Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28(4):339-50.
Tarantino G. Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? World J Gastroenterol 2007;13(35):4669-72.
Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M, Capone D, Pasanisi F. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it noninvasively? J Inflamm (Lond) 2009;6:6.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history ofnonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129(1):113–21.
Baumeister SE, Völzke H, Marschall P, John U, Schmidt CO, Flessa S, Alte D. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008;134(1):85–94.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P,Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalenceof hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40(6):1387–95.
Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96(10):2957—61.
Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G,Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122(2):274-80.
Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, O’Brien PE. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003;39(6):967-71.
Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P,Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19(8):854-8.
Struben VM, Hespenheide EE, and Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108(1):9-13.
Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99(2):292-8.
Zhanga L, Pua K, Chaib Z, Dixon JB. Family history of coronary heart disease is associated with a higher incidence of nonalcoholic fatty liver disease: Central obesity the likely link. Obes Res Clin Pract 2007;1:125-31.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
Moscatiello S, Manini R, Marchesini G. Diabetes and liverdisease: an ominous association. Nutr Metab CardiovascDis 2007;17(1):63-70.
Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR.Familial aggregation of insulin resistance in first-degreerelatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4(9):1162-9.
Hashemi M, Eskandari-Nasab E, Fazaeli A, Bahari A,Hashemzehi NA, Shafieipour S, Taheri M, Moazeni-Roodi A, Zakeri Z, Bakhshipour A, Ghavami S. Association of Genetic Polymorphisms of Glutathione-S-Transferase Genes (GSTT1, GSTM1, and GSTP1) and Susceptibility to Nonalcoholic Fatty Liver Disease in Zahedan, Southeast Iran. DNA Cell Biol 2011;31(5):672-7.
Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008 Jan 7;14(1):22-8.
Dagogo-Jack S, Egbuonu N, Edeoga C. Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. Med Princ Pract 2010;19(3):167-75.
Saad H, Sawan S, Rashed W, Zubaid M. Influence of diabetes on the outcome of acute coronary syndrome in Kuwait. Med Princ Pract 2010;19(2):113-7.
Schindhelm RK, Diamant M, Heine RJ. Nonalcoholic fattyliver disease and cardiovascular disease risk. Curr Diab,Rep 2007;7(3):181-7.
Ridker PM, Glynn RJ, Hennekens CH. C-reactive proteinadds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97(20):2007-11.
Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009;50(1):204-10.
Khedmat H, Fallahian F, Abolghasemi H, Hajibeigi B, Attarchi Z, Alaeddini F, Holisaz MT, Pourali M, Sharifi S, Zarei N. Serum gamma-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase activity in Iranian healthy blood donor men. World J Gastroenterol 2007;13(6):889-94.
Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipidand Glucose Study. Diabetes Res Clin Pract2003;61(1):29-37.
Al-Saeedi F, Loutfi I. (99m)Tc sulfur colloid and (99m)Tc mebrofenin hepatobiliary functional liver imaging in normal and diabetic rats. Med Princ Pract 2011;20(2):129-32.
Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, Shah SR, Rathi PM, Joshi AS, Thakkar H, Menon PS, Shah NS. Prevalence of nonalcoholic fatty liverdisease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009;57:205-10.
Targher G, Bertolini L, Padovani R, Rodella S, Tessari R,Zenari L, Day C, Arcaro G. Prevalence of nonalcoholicfatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care2007;30(5):1212-8.
Younossi ZM, Gramlich T, Matteoni CA, Boparai N,McCullough AJ. Nonalcoholic fatty liver disease inpatients with type 2 diabetes. Clin Gastroenterol Hepatol2004;2(3):262-5.
Adams LA, Waters OR, Knuiman MW, Elliott RR, OlynykJK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009;104(4):861-7.
Sargin M, Uygur-Bayramiçli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease withinsulin resistance: is OGTT indicated in nonalcoholic fattyliver disease? J Clin Gastroenterol 2003;37(5):399-402.
Chitturi S, Farrell GC. Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. JGastroenterol Hepatol 2007;22(7):967-9.
Johanson EH, Jansson PA, Lönn L, Matsuzawa Y, Funahashi T, Taskinen MR, Smith U, Axelsen M. Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. J Clin Endocrinol Metab 2003;88(9):4232-8.
Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, Testa R. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999;44(6):1249-53.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413-9.
Liberopoulos EN, Elisaf MS. Dyslipidemia in patients with thyroid disorders. Hormones (Athens) 2002;1(4):218-23.
Facchini F, Chen YD, Clinkingbeard C, Jeppesen J, Reaven GM. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family historyof hypertension. Am J Hypertens 1992;5(10):694-9.